Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) has officially changed its legal name from Cybin Inc. to Helus Pharma Inc., effective Oct. 1, 2026. The change, approved by shareholders at the company's Sept. 22 annual and special meeting, follows the adoption of the Helus Pharma business name in January and underscores the company's anticipated evolution from a clinical-stage discovery and development outfit into a commercial-ready pharmaceutical company. For investors, the rebranding is more than a cosmetic shift: it signals that Helus Pharma is positioning itself for the next phase of growth, one that may involve regulatory milestones, market launches, and a broader commercial strategy.
The name change comes at a pivotal time for the company, which is developing novel serotonergic agonists (NSAs) to address significant unmet needs in mental health. Its lead candidate, HLP003, is in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Another candidate, HLP004, is in Phase 2 for generalized anxiety disorder. These programs target conditions affecting millions worldwide, and successful commercialization could position Helus Pharma as a key player in the neuropsychiatric space. The transition to a commercial-ready identity may also enhance the company's ability to attract partnerships, financing, and talent.
Existing shareholders are not required to take any action, and the company's common shares will continue trading under the ticker HELP on the Nasdaq Global Market and Cboe Canada. That continuity is important because it preserves liquidity and avoids disruption for investors who have backed the company's scientific vision. The legal name change, however, could affect how the company is perceived by the broader market. A commercial-ready pharmaceutical company often commands different valuation metrics and investor expectations than a clinical-stage biotech, and the rebranding may help align Helus Pharma's public image with its late-stage pipeline.
Helus Pharma, founded in 2019, operates in Canada, the United States, the United Kingdom, and Ireland. Its proprietary NSAs are synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity, potentially offering durable improvements in mental health. With class-leading data, the company aims to improve the treatment landscape for depression, anxiety, and other conditions. More information about Helus Pharma is available at www.helus.com.
The announcement was disseminated through MissionIR, a communications platform that provides syndicated content to enhance visibility for public companies. MissionIR is part of the Dynamic Brand Portfolio at IBN, which offers access to wire solutions via InvestorWire, editorial syndication to 5,000+ outlets, and social media distribution. For more details, visit MissionIR or the full disclaimer at https://www.MissionIR.com/Disclaimer.
For investors, the name change is a clear signal that Helus Pharma is preparing for a future beyond clinical trials. As the company advances its pipeline toward potential approval and commercialization, its new identity may help it stand out in a competitive biotech landscape. The move also reflects a broader trend of clinical-stage companies rebranding to better communicate their commercial ambitions, a strategy that can influence investor confidence and market positioning. How the market responds in the coming months will be closely watched, especially as Helus Pharma approaches key data readouts and regulatory interactions.
